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ABSTRACT Pulmonary hypertension is a potentially fatal disease. Despite pharmacological advances in
pulmonary hypertension, fatigue remains common in patients with pulmonary hypertension.
A convenience sample of 120 participants at an international patient conference completed the
Multidimensional Fatigue Inventory (MFI)-20 scale. Data on New York Heart Association Functional
Class, body mass index, oxygen use and medication type/use were also collected.
There was a high prevalence of “severe” to “very severe” fatigue for each dimension: General Fatigue
(60%), Physical Fatigue (55.8%), Reduced Activity (41.7%), Reduced Motivation (32.5%) and Mental
Fatigue (27.5%). The mean±SD overall MFI-20 score was 58±5.1. Dimensions with the highest averaged
levels were General Fatigue (13.40±3.61), Physical Fatigue (13.23±3.67) and Reduced Activity (11.33±4.16).
Body mass index correlated with higher fatigue scores. Phosphodiesterase inhibitor plus endothelin
receptor antagonist combination negatively predicted General Fatigue, Physical Fatigue, Reduced
Motivation and Reduced Activity. Triple therapy was a significant predictor of General Fatigue, Physical
Fatigue and Reduced Activity. There were no significant predictors of Mental Fatigue.
Multidimensional fatigue is common and severe in patients with pulmonary hypertension. Phosphodiesterase
inhibitor plus endothelin receptor antagonist combination resulted in lower scores in most fatigue dimensions.
Comprehensive assessment of fatigue should be considered in the clinical care of patients with pulmonary
hypertension and clinical research to develop formal interventions that target this disabling symptom.
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ORIGINAL ARTICLE
PULMONARY VASCULAR DISEASES
Introduction
Pulmonary hypertension affects 12.4 per million people in the USA [1]. Aetiologies of pulmonary
hypertension are diverse; however, dyspnoea is the most recognised symptom. Fatigue, defined as lack of
energy or increased sense of effort with routine tasks, is a common, distinct symptom, but less clinically
recognised [2, 3]. Clinically significant fatigue occurs in 57% patients with pulmonary hypertension [2]
and is reported as a primary disabling symptom as frequently as dyspnoea [4]. Little research has focused
on patient experience, associative factors or impact of fatigue on function and health-related quality of life
(HRQoL) in pulmonary hypertension [5].
Pulmonary hypertension-related functional impairment leads to difficulties maintaining/finding
employment [2, 6, 7], potential hopelessness and anxiety stemming from fear of disease/symptom
progression, and loss of social engagement [6–8]. Fatigue is generally associated with similar negative
impact on HRQoL [9–13], suggesting a potential causative overlay in pulmonary hypertension HRQoL.
Despite pharmacological advances, fatigue remains an underrecognised and unaddressed symptom of
pulmonary hypertension. Here, we examine: 1) prevalence and severity of fatigue as a multidimensional
symptom, 2) differences in demographic characteristics and pulmonary hypertension severity indicators,
and 3) pulmonary hypertension therapy associated with and predictive of fatigue.
Methods
Patients
Upon approval by the Pulmonary Hypertension Association (PHA) and the researchers’ Institutional
Review Board, data were collected onsite at the PHA 11th International Pulmonary Hypertension
Conference and Scientific Sessions (Indianapolis, IN, USA) in 2014. All subjects registered with the PHA
as both patients and research participants completed demographic questionnaires prior to enrolment
allowing for patient queries to their physician.
Patients aged between 18 and 80 years with an established pulmonary hypertension diagnosis from any
World Health Organization (WHO) group as self-reported on the PHA research form were included.
Enquiry into literacy and communication vulnerabilities ascertained need for onsite assistance to complete
the surveys.
Multidimensional Fatigue Inventory
Although not validated in pulmonary hypertension, the Multidimensional Fatigue Inventory (MFI)-20 was
chosen as a sensitive instrument that could differentiate and examine, and thus provide an understanding
of the severity and types of fatigue experienced in, people living with pulmonary hypertension. The
MFI-20 precisely accommodates a cross-sectional examination of fatigue as a multidimensional
phenomena, providing both total and dimensional subscale scores [14]. The MFI-20 is a patient-reported
questionnaire developed in 1995, and is widely used in cancer and other chronic illnesses. It requires 5–10
min to complete and contains 20 items under five subscales (General Fatigue, Mental Fatigue, Physical
Fatigue, Reduced Activity and Reduced Motivation), each with four items (two positively and two
negatively worded items) rated on a 5-point Likert scale. Higher scores indicate higher fatigue levels.
Dimension scores are categorised as mild (5–8), moderate (9–12), severe (13–16) and very severe (17–20).
A total MFI score is used, but is less well validated and subject to underestimation of fatigue.
The MFI-20 is internally consistent and validated with Cronbach’s α>0.80 for the five subscales of fatigue
[14], with good construct validity, good convergent and discriminant correlations with the visual analogue
scale [14], and strong correlation with the Short Form-36 [15]. It has a minimal clinically important
difference of 2 points in cancer-related investigations [16].
Study variables and instruments
Attestation of pulmonary hypertension diagnosis, WHO group (with subcategorisation, e.g. connective
tissue disease), physician contact information, age, race, ethnicity, height, weight, oxygen use, New York
Heart Association (NYHA) Functional Class [17], and pulmonary hypertension and nonpulmonary
hypertension medication, dose and duration of use were collected. Month/year and age at diagnosis were
collected on the PHA form, but not the initial onset of symptoms, leaving an ability to project disease
duration.
Procedure
Unscheduled voluntary enlistment occurred in response to a PHA programme describing the project as
“patient perspective of living with pulmonary hypertension” without indicating fatigue. Research sites were
assigned by PHA and in an accessible location. After obtaining informed consent, MFI-20 was
administered electronically via iPads with paper and verbal interview options available.
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Statistical analysis
An a priori power analysis for multiple regression using G*Power 3 (www.gpower.hhu.de) (power=0.80,
α=0.05) yielded a minimum sample size of 98 to detect a medium effect.
SPSS version 22.0 (IBM, Armonk, NY, USA) was used to analyse basic descriptive statistics. Skewness and
kurtosis statistics were examined, with all data approximating a normal distribution. Depending on
variable type, appropriate statistical analyses examined relationships (i.e. Pearson correlations, independent
t-tests or ANOVAs). Prior to hierarchical regression analyses, bivariate correlations examined all predictors
and outcome variables (i.e. fatigue dimensions). Point biserial (rpb) correlations were applied to
dichotomous and continuous variables. Controlling for type I error (impact of multiple comparisons), the
Bonferroni correction was applied (α=0.05/5=0.01).
Results
Participants
The entire cohort of 120 participants (300 total PHA attendees) completed all items and were WHO
group I (55.8% (n=67) idiopathic, 13.3% (n=16) connective tissue disease related), with a mean±SD age of
52.61±14.0 years (range 21–79 years); 88.3% (n=106) were female and 85.8% (n=103) were White, with
48.3% (n=58) classifiable as “obese” (BMI ⩾30 kg·m−2) (table 1).
The largest proportions were NYHA Functional Class II (n=70 (58.3%)) and III (n=35 (29.2%)), with
52.5% (n=63) requiring supplemental oxygen.
Medications
Prostacyclin (prostaglandin I2 (PGI2)), phosphodiesterase inhibitor (PDEI) and endothelin receptor
antagonist (ERA) use occurred in 63 (52.5%), 83 (69.2%) and 59 (49.2%) of participants, respectively. 32
(26.7%) participants were on single, 52 (43.3%) on dual and 23 (19.2%) on triple combination therapy. For
dual therapy, PDEI+PGI2 was used in 25 (20.8%), PDEI+ERA in 20 (16.7%) and PGI2+ERA in seven
(5.8%) participants.
MFI psychometric and descriptive information
Reduced Activity and Mental Fatigue subscales had the highest internal consistency (α=0.775 and 0.798,
respectively). The General Fatigue, Reduced Motivation and Physical Fatigue dimensions were slightly
lower (α=0.651, 0.687 and 0.679, respectively). Skewed distribution was examined for each dimension with
additional assessment for >15% of respondents achieving the highest level indicating a ceiling effect. For
all subscales, no ceiling effects were present.
Prevalence and severity of fatigue in pulmonary hypertension
The mean±SD total score was 58±5.1. Of participants scoring “severe”/“very severe” (figure 1), General Fatigue
(13.40±3.61, n=72 (60.0%)) and Physical Fatigue (13.23±3.67, n=67 (55.8%)) had higher mean scores than
other subscales (F=34.612, d.f.=4, 116; p<0.0001), followed by Reduced Activity (11.33±4.16, n=50 (41.7%)),
Mental Fatigue (10.42±3.98, n=39 (32.5%)) and Reduced Motivation (10.30±3.59; n=33 (27.5%)).
Patient characteristics and fatigue
Neither the MFI-20 dimensions nor total scores demonstrated significant differences in age, sex and race
(table 2).
No significant differences occurred between the “idiopathic” and other groups, including between the
connective tissue disease group (p>0.05 on all dimensions and total score).
BMI was dichotomised into “obese”(⩾30 kg·m−2) and “less than obese” (⩽29.9 kg·m−2), combining
“overweight”, “healthy” and “underweight”. Mean±SD total scores were higher for “obese” (64.41±15.24;
p<0.001) than “less than obese” (53.34±13.08), and in three dimensions: Reduced Activity (p<0.001),
Physical Fatigue (p=0.002), with the largest differences in Mental Fatigue (12.34±3.84 versus 8.63±3.21;
p<0.001).
Pulmonary hypertension severity indicators
Compared with NYHA Functional Class I/II, Functional Class III/IV had higher mean±SD total MFI-20
(67.26±11.61 versus 54.57±14.99; p<0.001) and in four dimensions: Reduced Activity (13.74±3.31 versus
10.17±4.05; p<0.0001), Reduced Motivation (12.49±3.22 versus 9.25±3.28; p<0.0001), Physical Fatigue
(14.54±2.63 versus 12.60±3.94; p=0.002) and Mental Fatigue (12.64±3.89 versus 9.36±3.58; p<0.0001).
Patients using supplemental oxygen demonstrated higher mean±SD total scores (62.62±13.27 versus
54.35±16.03; p=0.003) and in all five dimensions: Reduced Activity (p=0.034), Reduced Motivation
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(p=0.036), General Fatigue (p=0.003), Physical Fatigue (p=0.042), with the largest differences in Mental
Fatigue scores (11.37±3.74 versus 9.39±3.99; p=0.006).
Pulmonary hypertension medications
Pulmonary hypertension medication associations with fatigue
Medications (table 3) were grouped by class. PGI2 (11.00±3.67) single use displayed higher Reduced
Motivation (9.60±3.39; p=0.032) than PDEI or ERA single use.
Regarding dual therapy, PGI2+PDEI had higher total (62.68±14.24; p=0.020), Reduced Motivation
(11.32±3.62; p=0.012) and General Fatigue (14.49±3.59; p=0.007) scores. PGI2+ERA use had higher total
(63.92±13.67; p=0.046) and General Fatigue (14.92±3.48; p=0.015) scores. PGI2+PDEI+ERA demonstrated
higher Reduced Motivation (11.90±4.06; p=0.023), General Fatigue (15.57±3.20; p=0.002) and Mental
Fatigue (12.05±4.60; p=0.039) scores.
TABLE 1 Patient characteristics
Subjects 120
Age years 52.61±14.0
Sex
Male 14 (11.7)
Female 106 (88.3)
Race
White 103 (85.8)
Other 17 (14.2)
African-American/Black 7 (5.8)
Hispanic or Latino 6 (5.0)
Asian 2 (1.7)
Native American 2 (1.7)
BMI
Less than obese 62 (51.7)
Underweight (BMI <18.5 kg·m−2) 2 (1.7)
Healthy weight (BMI 18.5–24.9 kg·m−2) 27 (22.5)
Overweight (BMI 25.0–29.9 kg·m−2) 33 (27.5)
Obese (BMI ⩾30 kg·m−2) 58 (48.3)
WHO group I breakdown
Idiopathic 67 (55.8)
Other 53 (44.2)
Connective tissue disease 16 (13.3)
Unknown 13 (10.8)
Congenital heart disease 7 (5.8)
Drug/toxin induced 4 (3.3)
Heritable 3 (2.5)
Idiopathic with heritable 3 (2.5)
Other 7 (5.7)
NYHA Functional Class
I/II 81 (67.5)
I 11 (9.2)
II 70 (58.3)
III/IV 39 (32.5)
III 35 (29.2)
IV 4 (3.3)
Oxygen use 63 (52.5)
Medications
PGI2 8 (6.6)
PDEI 15 (12.5)
ERA 9 (7.5)
PGI2+PDEI 25 (20.8)
PGI2+ERA 7 (5.8)
PDEI+ERA 20 (16.7)
PGI2+PDEI+ERA 23 (19.2)
Data are presented as n, mean±SD or n (%). BMI: body mass index; WHO: World Health Organization;
NYHA: New York Heart Association; PGI2: prostaglandin I2; PDEI: phosphodiesterase inhibitor; ERA:
endothelin receptor antagonist.
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Medication predictors of fatigue in pulmonary hypertension
Hierarchical multiple regression analyses supported positive relationships found between PGI2 (rpb=0.201,
p=0.027), PGI2+PDEI (rpb=0.240, p=0.008) and triple therapy (rpb=0.196, p=0.032) with Reduced
Motivation, as well as between PGI2 (rpb=0.197, p=0.031), PGI2+ERA (rpb=0.263, p=0.004), PGI2+PDEI
(rpb=0.257, p=0.005) and triple therapy (rpb=0.311, p=0.001) with General Fatigue.
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FIGURE 1 Distribution of fatigue severity among the Multidimensional Fatigue Inventory-20 fatigue
dimensions.
TABLE 2 Fatigue dimension and patient# characteristics
Patients Reduced
Activity
Reduced
Motivation
General
Fatigue
Physical
Fatigue
Mental
Fatigue
Total
Sex
Male 14 11.21±2.99
(5–15)
9.57±2.90
(5–14)
12.43±3.06
(7–18)
12.79±2.88
(7–17)
10.36±3.39
(6–17)
56.36±12.07
(34–71)
Female 106 11.35±4.31
(4–20)
10.40±3.67
(4–20)
13.53±3.67
(4–20)
13.29±3.77
(4–20)
10.43±4.06
(4–20)
59.00±15.16
(26–92)
Race
White 103 11.46±4.16
(4–20)
10.51±3.56
(4–20)
13.55±3.56
(5–20)
13.36±3.66
(4–20)
10.42±3.90
(4–20)
59.30±14.75
(27–92)
Other 17 10.59±4.23
(4–17)
9.00±3.61
(4–18)
12.47±3.91
(4–19)
12.47±3.73
(6–20)
10.47±4.57
(4–19)
55.00±17.50
(26–87)
BMI
Less than obese 62 9.85±3.79
(4–20)
9.52±3.42
(4–20)
13.11±3.27
(6–20)
12.23±3.72
(4–19)
8.63±3.21
(4–18)
53.34±13.08
(26–78)
Obese 58 12.91***±3.99
(4–20)
11.14*±3.61
(4–19)
13.71±3.95
(4–20)
14.31**±3.32
(7–20)
12.34***±3.84
(4–20)
64.41***±15.24
(26–92)
PAH
Idiopathic 67 11.28±4.33
(4–20)
10.37±3.87
(4–20)
13.40±3.60
(5.20)
13.58±4.06
(4–20)
10.54±4.19
(4.20)
59.18±16.08
(26–91)
Other 53 11.40±3.98
(4–20)
10.21±3.24
(4–19)
13.40±3.66
(4–20)
12.79±3.09
(6–20)
10.28±3.72
(4–19)
58.08±14.03
(26–92)
NYHA Functional Class
I/II 81 10.17±4.05
(4–20)
9.25±3.28
(4–20)
13.19±3.89
(4–20)
12.60±3.94
(4–20)
9.36±3.58
(4–20)
54.57±14.99
(26–91)
III/IV 39 13.74***±3.31
(6–20)
12.49***±3.22
(6–19)
13.85±2.95
(8–20)
14.54**±2.63
(10–20)
12.64***±3.89
(5–20)
67.26***±11.61
(43–92)
Oxygen use 63 12.10*±4.17
(4–20)
10.95*±3.44
(4–20)
14.32**±3.11
(6–20)
13.89*±3.13
(6–20)
11.37**±3.74
(4–20)
62.62**±13.27
(27–92)
Data are presented as n or mean±SD (minimum–maximum). BMI: body mass index; PAH: pulmonary arterial hypertension; NYHA: New York
Heart Association. For oxygen use, only “Yes” descriptive statistics are reported. #: n=120 patients. *: p<0.05; **: p<0.01; ***: p<0.001.
Asterisks follow the higher mean for the fatigue dimension.
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Triple therapy (p<0.05) predicted General Fatigue, while PDEI+ERA (p<0.05) predicted reduced General
Fatigue.
PDEI use alone (p<0.05) and triple therapy (p<0.01) were significant predictors of Physical Fatigue, while
PGI2+ERA (p<0.05) and PDEI+ERA (p<0.01) predicted reduced Physical Fatigue.
For Mental Fatigue, no significant medication regimen predictors were identified.
PDEI+ERA (p<0.05) predicted lower fatigue scores in Reduced Motivation.
PDEI (p<0.01) single use, ERA single use (p<0.01) and triple therapy (p<0.01) predicted Reduced
Motivation, while PDEI+ERA (p<0.001) predicted low scores in Reduced Activity.
Discussion
This is the first investigation to characterise multidimensional aspects of fatigue in group I pulmonary
hypertension demonstrating a severity prevalence comparable to that of cancer [18] and higher than
rheumatoid arthritis [19], and calls for further investigation into pulmonary hypertension-related fatigue.
The identification and management of fatigue in pulmonary hypertension has been outside the purview of
current pulmonary hypertension treatment strategies. Despite participants possessing health and
self-efficacy sufficient for conference attendance, fatigue severity was high. Regardless, fatigue remains an
underrecognised clinical and research concern, and is likely influenced by the total pulmonary
hypertension experience of disease process, medication/management and psychosocial effects.
The MFI-20 has face validity and demonstrated feasibility in both time and scoring, but has not yet been
validated for use in pulmonary hypertension. The MFI-20, broadly validated in other diseases, provides a
granular assessment into the types of fatigue that contribute to a patient’s pulmonary hypertension
experience, providing an opportunity for clinical recognition, anticipatory education and prescription
strategies such as supervised physical training to enhance/protect peripheral muscle strength and reserve.
Further results indicate higher scores in General Fatigue and dimensions of physical function, i.e. Physical
Fatigue and Reduced Activity.
Neither age, sex or race had significant association on fatigue severity in any dimension. Not surprisingly,
differences in total fatigue and dimensions were with higher NYHA classification and oxygen use. Oxygen
use was associated with higher scores in all dimensions. In addition to the systemic effects of hypoxia,
daily logistical burdens of management with the cumbersome weight and organisation of equipment may
impact dimensional fatigue.
Appearing contradictory, NYHA Functional Class III/IV was related to higher scores in the total and all
subscales except General Fatigue; however, the total averaged score was still very high as was NYHA
Functional Class I/II (though statistically lower). Given our negative investigations into a ceiling effect, this
TABLE 3 Fatigue dimension scores and medication use
Subjects Reduced Activity Reduced Motivation General Fatigue Physical Fatigue Mental Fatigue Total
PGI2 8 11.42±3.98
(4–20)
11.00*±3.67
(4–20)
14.00±3.71
(5–20)
13.65±3.57
(4–20)
11.03±4.33
(4–20)
61.10±14.54
(28–91)
PDEI 15 11.51±4.02
(4–20)
10.63±3.64
(4–20)
13.77±3.39
(5–20)
13.43±3.51
(4–20)
10.57±4.03
(4–20)
59.90±14.51
(27–92)
ERA 9 11.42±4.17
(4–19)
10.31±4.00
(4–20)
13.73±3.66
(5–20)
12.88±4.00
(5–20)
10.17±4.14
(4–19)
58.52±15.98
(26–87)
PGI2+PDEI 25 11.79±3.97
(4–20)
11.32*±3.62
(4–20)
14.49**±3.59
(5–20)
13.81±3.57
(4–20)
11.28±4.48
(4–20)
62.68*±14.24
(28–91)
PGI2+ERA 7 12.19±3.50
(4–19)
11.50±3.87
(4–20)
14.92*±3.48
(5–20)
13.46±3.73
(5–20)
11.85±4.54
(4–19)
63.92*±13.67
(33–87)
PDEI+ERA 20 11.03±3.96
(4–19)
10.42±4.15
(4–20)
13.92±3.46
(5–20)
12.81±3.64
(6–20)
10.53±4.40
(4–19)
58.69±15.55
(27–87)
PGI2+PDEI+ERA 23 12.71±3.33
(5–19)
11.90*±4.06
(4–20)
15.57**±3.20
(5–20)
14.00±3.52
(7–20)
12.05*±4.60
(4–19)
66.24*±12.78
(34–87)
Data are presented as n or mean±SD (minimum–maximum). PGI2: prostaglandin I2; PDEI: phosphodiesterase inhibitor; ERA: endothelin
receptor antagonist. Only “Yes” descriptive statistics are reported. *: p<0.05; **: p<0.01. Asterisks follow the higher mean for the fatigue
dimension.
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may speak to a yet unrecognised aspect of fatigue specific to pulmonary hypertension captured within the
other dimensions which might be elucidated through qualitative mixed methods studies.
Several interesting findings regarding medication emerged when controlling for severity indicators, most
notably the predictive impact of PDEI+ERA with lower fatigue scores in all dimensions except for Mental
Fatigue, which is encouraging given recent regulatory approval of this specific combined therapy [20].
However, addition of PGI2, when controlling for NYHA Functional Class and oxygen use, was strongly
predictive of higher General Fatigue, Physical Fatigue and Reduced Activity scores by >6 points, while 2
points is the accepted minimal clinically important difference [15]. These findings at face value make
sense. Targeting pulmonary arterial hypertension at two different vasoconstrictive pathways using
medications that are most tolerable in pulmonary arterial hypertension (PDEI and ERA) improves the
vasodilatory response without escalating the patient burden of side-effects. However, prostacyclins (PGI2)
have a high side-effect profile and are logistically burdensome in terms of administration and
self-management. An equally reasonable consideration is that patients on PGI2 and in any combination
may be perceived to have more severe disease, and thus higher fatigue scores.
Elevated BMI was associated with higher scores in all but General Fatigue. Whether weight management
favourably impacts pulmonary hypertension fatigue is yet to be investigated. Safe exercise and nutrition,
however, are healthful activities that may provide targeted improvement in deconditioning-related
pulmonary hypertension fatigue.
Mental Fatigue was predominantly mild to moderate without significant beneficial or pejorative impact by
pulmonary hypertension medications. However, this dimension was severe/very severe for 35% of
participants and found to be higher with oxygen use, NYHA Functional Class III/IV and triple therapy.
These findings likely speak to strata of disease severity, and require investigation into self-management and
clinician-directed strategies to preserve perceived brain function and thus potentially HRQoL.
Complete alleviation of pulmonary hypertension fatigue may not be a realistic goal; however, strategies to
minimise the distress of fatigue severity are a worthy effort, as has been shown in multiple sclerosis, cancer
and other disease processes [21–27]. Pharmaceutical interventions such as methylphenidate may have an
overall pejorative impact on pulmonary hypertension health outcomes, with others such as modafinil
being unknown in patients with vascular disease. Large cohorts demonstrated efficacy without discernible
toxicity of American ginseng in cancer-related fatigue [27]. Nonpharmacological interventions have been
successfully utilised to reduce cancer-related fatigue, such as mindfulness meditation, yoga and tai chi, as
well as dance and other exercise [21, 22, 24, 26, 27].
This study has several limitations. Although use of the MFI-20 makes sense hypothetically and
demonstrated internal consistency in this study, it is not fully validated in pulmonary hypertension. The
study’s cross-sectional nature is unable to assess instrument discrimination of fatigue changes over time
and thus unable to contribute to validation of the MFI-20 for specific use in pulmonary hypertension.
Comparative studies with other fatigue instruments, such as PROMIS [28], would be important before
using the MFI-20 as a secondary outcome measure in pulmonary hypertension clinical trials. Participants
attending the PHA conference may not be representative of the overall pulmonary hypertension
population, raising questions of selection bias as well as lack of a control group. Furthermore, risk status
for untreated obstructive sleep apnoea was not assessed, which would be an important confounding
variable for fatigue severity especially in patients with elevated BMI. Nevertheless, results from this study
provide direction in identifying dimensions of fatigue as experienced in pulmonary hypertension, a
complex disease involving a symptom, dyspnoea, which in itself is physically exhausting, with downstream
fatigue-associated sequelae of oxygen deprivation on cognition, systemic vasculature, and muscle and nerve
health. This study demonstrates severity levels similar to those in rheumatological and oncological
conditions [18, 19], and provides guidance on identifying patients at risk for fatigue type, potential
enhancements to consider in relation to predictors of fatigue and investigations in total patient-centred
care in pulmonary hypertension that targets strategies by fatigue type.
Furthermore, much of the data is collected by PHA without medical record validation, and lacking
potentially influential information such as disease duration and haemodynamics. This is primarily
concerning WHO group designation, which is the only third-party communication (doctor to patient),
whereas all other data is first-party reported (known intrinsically by the patient). This limitation might be
more serious if our WHO group proportion conflicted with the distribution of past PHA conference
attendances, which is predominantly group I and very few other groups in attendance. Although no
significant differences in fatigue were found between the idiopathic and connective tissue disease groups,
sample size differences were large, possibly influencing the analysis.
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Tandem assessment of standard HRQoL, depression, sleep quality or dyspnoea questionnaires was not
attempted for correlative analysis [5, 29] with reasoning that conference attendance is frenetic and
exhausting, albeit an exciting experience for patients. Prolonged participation time might have interfered
with either research involvement or attendance at important educational sessions. For this reason, it was
pre-determined to reserve introduction of correlative instruments for future nonconference cohorts.
In rheumatoid arthritis, symptom-querying focus groups identified fatigue as important to patients and
subsequently validated it for inclusion as a reliable, discriminatory measure for clinical trial use [30]. It is
yet unknown which currently available fatigue scale provides the most accurate and discriminatory
reflection of pulmonary hypertension fatigue, but continued qualitative investigations will identify content
and language relevant to people living with pulmonary hypertension, and further define the relevance of
MFI-20 and other fatigue instruments, potentially revealing a need for a pulmonary hypertension-specific
fatigue or HRQoL instrument. The Cambridge Pulmonary Hypertension Outcome Review [31] may have
been one such instrument, but its costliness prohibits use in clinical settings and nonpharmaceutical
research, and thus it remains unavailable to most patient-centred and patient care efforts in pulmonary
hypertension.
Examination of longitudinal correlates with pulmonary hypertension fatigue such as haemodynamic
coordinates, disease duration, mental health, HRQoL, illness behaviour and symptom interference is
needed [32]. Pilot investigations of nonpharmacological therapies targeting pulmonary
hypertension-specific fatigue are warranted. The authors currently recommend use of the MFI-20 with
concurrent use of the fatigue visual analogue scale and at least one additional fatigue instrument until a
fully validated instrument in pulmonary hypertension is identified.
Conclusions
Significant fatigue severity was detected in group I pulmonary hypertension, particularly in General
Fatigue, Physical Fatigue and Reduced Activity, potentially indicating priority areas of targeted
intervention. BMI was associated with higher scores, prompting consideration of weight management for
symptom amelioration. PDEI+ERA therapy predicted favourable impact on fatigue dimensions, while
addition of PGI2 predicted worse fatigue scores. Continued investigations into fatigue assessment may
provide important data regarding the utility of fatigue as a discriminatory measure in pulmonary
hypertension and, very importantly, development of targeted interventions to alleviate and/or manage
fatigue.
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